Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,674 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies.
Mostaghimi A, Ko J, Tosti A, McMichael A, Ohyama M, Ito T, Dutronc Y, Ball S, Yu G, Murage M, Chen YF, Chiasserini C, Wollenberg A. Mostaghimi A, et al. Among authors: ito t. J Am Acad Dermatol. 2024 Oct;91(4):729-732. doi: 10.1016/j.jaad.2024.05.077. Epub 2024 Jun 7. J Am Acad Dermatol. 2024. PMID: 38852742 Free article. No abstract available.
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, Yu G, Chiasserini C, McCollam J, Wu WS, King B. Kwon O, et al. Among authors: ito t. Am J Clin Dermatol. 2023 May;24(3):443-451. doi: 10.1007/s40257-023-00764-w. Epub 2023 Mar 1. Am J Clin Dermatol. 2023. PMID: 36855020 Free PMC article. Clinical Trial.
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. King B, et al. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. N Engl J Med. 2022. PMID: 35334197 Clinical Trial.
Long-term survival analysis based on tumor location in patients with pancreatic ductal adenocarcinoma who underwent pancreatectomy following neoadjuvant chemoradiotherapy.
Kaluba B, Kuriyama N, Sakamoto T, Komatsubara H, Maeda K, Noguchi D, Gyoten K, Ito T, Hayasaki A, Fujii T, Iizawa Y, Murata Y, Tanemura A, Kishiwada M, Mizuno S. Kaluba B, et al. Among authors: ito t. Langenbecks Arch Surg. 2025 Jan 22;410(1):47. doi: 10.1007/s00423-025-03609-8. Langenbecks Arch Surg. 2025. PMID: 39838137
Clinical features and pathological findings by liver biopsy in patients with immune-related sclerosing cholangitis induced by immune checkpoint inhibitors.
Yasuda T, Ito T, Ishikawa T, Mizuno K, Yamamoto T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Honda T, Koshiyama Y, Yasuda S, Toyoda H, Ando Y, Shimoyama Y, Kawashima H. Yasuda T, et al. Among authors: ito t. Dig Liver Dis. 2025 Jan 18:S1590-8658(25)00038-6. doi: 10.1016/j.dld.2025.01.037. Online ahead of print. Dig Liver Dis. 2025. PMID: 39828442
Transcriptome analysis of human oral squamous cancer SAS cells as an early response after boron neutron capture therapy.
Imamichi S, Ito T, Tong Y, Gao Z, Arai Y, Fujimori H, Chen L, Sanada Y, Nakamura S, Murakami Y, Ishiai M, Suzuki M, Itami J, Igaki H, Masunaga S, Masutani M. Imamichi S, et al. Among authors: ito t. Appl Radiat Isot. 2025 Jan 2;218:111648. doi: 10.1016/j.apradiso.2024.111648. Online ahead of print. Appl Radiat Isot. 2025. PMID: 39827644
11,674 results
You have reached the last available page of results. Please see the User Guide for more information.